Introduction
Tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) and fibroblast growth factor-inducible 14 (Fn14) are a TNF superfamily ligand-receptor pair implicated in the pathogenesis of several diseases including chronic inflammatory diseases, stroke and cancer (1) . In the cancer setting, TWEAK and Fn14 are expressed in tumor tissue and TWEAK can activate several cellular processes associated with tumor progression such as proliferation, invasion, angiogenesis and inflammation (1, 2) . However, the downstream functional consequences of TWEAK binding to Fn14 appear to depend on cellular context. For example, although TWEAK treatment of certain tumor cell lines can induce cell death (3, 4) , TWEAK treatment of other tumor lines, for example glioma cell lines, does not cause cell death, but instead promotes cell migration (5) and enhanced survival following chemotherapeutic drug exposure (6, 7) .
The Fn14 receptor is expressed at relatively low levels in normal tissues, but it is dramatically elevated locally in injured tissues, where it plays a role in tissue remodeling (1) . In addition, the Fn14 gene is overexpressed in multiple solid tumor types relative to matched adjacent normal tissue or normal tissue from non-diseased donors (5, (8) (9) (10) (11) (12) .
Some of these prior Fn14 overexpression reports also included data indicating that Fn14 expression levels positively correlate with tumor progression (5, 10, 11) and poor patient outcome (9) . The fact that Fn14 expression is elevated in tumors as compared to normal tissue suggests that it may be a potential tumor antigen, and therefore, on the basis of expression alone, a valuable therapeutic target. Recently, Culp et al. (8) was efficacious in a range of tumor xenograft models, including colorectal, breast, renal, skin and head/neck cancer models. These authors suggested that the antitumor effects occurred through both direct cell growth inhibition and antibody-dependent cellular cytotoxicity (ADCC) mechanisms. In consideration of these findings, this group and others (13) have proposed that therapeutic activation of the TWEAK/Fn14 pathway may represent a novel modality to inhibit tumor growth.
The use of monoclonal antibodies, ligands, DARPins (designed ankyrin repeat proteins) (14) , and adnectins (15) for the delivery of highly cytotoxic molecules to specific target cells has gained wide acceptance and significant prominence in the field of targeted therapy. There are now several antibody-drug conjugates in clinical development and there are a number of toxin-based therapeutics under development and approved for use (16, 17) . The broad tumor expression coupled with limited normal expression makes Fn14 an attractive candidate for a targeted therapeutic approach. We have developed an immunoconjugate designated ITEM4-rGel containing a high-affinity anti-Fn14 monoclonal antibody conjugated to recombinant gelonin (rGel), a highly cytotoxic, ribosome-inactivating n-glycosidase. Herein, we report that this immunoconjugate can Fn14-deficient mouse embryonic fibroblasts (MEF 3.5-/-) were maintained in DMEM. All media contained 10% fetal bovine serum. Cells were grown at 37°C with 5% CO 2 at constant humidity. Media and supplements were purchased from Invitrogen (Grand Island, NY).
Construction and purification of the ITEM4-rGel conjugate
A 3-fold molar excess of the cross-linker N-succinimidyl-3-(2-pyridylodithio) propionate (SPDP; Pierce, Rockford, IL) was added to 2 mL of ITEM-4 (5 mg/ml in PBS), and allowed to react for 30 min at room temperature. Excess, unreacted SPDP was removed by gel filtration using Sephadex G-25 (Amersham Biosciences, Uppsala, Sweden) gel chromatography. Recombinant gelonin (5-fold molar excess versus ITEM-4) was reduced by adding 2 mM DTT (Sigma, St. Louis, MO) and stirring for 30 min at room temperature. Excess, unreacted DTT was removed by Sephadex G-25 gel chromatography. ITEM4-SPDP was slowly added to the rGel-DTT, with stirring, and the conjugation was allowed to proceed for 6 h at 4 °C under N 2 gas. Iodoacetamide (Sigma) was then added to a concentration of 2 mM to block any remaining, unconjugated ITEM-4. Unconjugated rGel was removed by passage through a Superose S-75 fast protein liquid chromatography column (Amersham). The concentration of NaCl was reduced to <10 mM by dilution, and the conjugate was applied to a Blue Sepharose (Amersham) column. Unconjugated ITEM-4 was eluted by washing with PBS (10 mM sodium phosphate, 150 mM NaCl, pH 7.2), and the conjugate was eluted with 10 mM sodium phosphate, 2 M NaCl. The purified conjugate was dialyzed into PBS and concentrated using an Amicon Ultra filter (Millipore, Billerica, MA). Endotoxin levels were determined with the QCL-1000 kit (Lonza Inc, Walkersville, MD), according to the manufacturer's instructions. If the level was above 50 EU/mg protein, the sample was slowly passed through an Acrodisc Mustang Q membrane, and the endotoxin levels were then re-assessed. The final conjugate preparations were then aliquoted and stored at -20
°C.

Flow cytometry
To analyze Fn14 cell surface expression and cell binding activity of ITEM4-rGel, flow cytometric analysis of cells stained with ITEM-4 or ITEM4-rGel was performed as previously described (18) . Briefly, 5×10 
Surface plasmon resonance assay
Binding of ITEM-4 and ITEM4-rGel to immobilized, recombinant Fn14 extracellular domain (Cell Sciences) was measured using a BIACore 3000 instrument as previously described (19) . The binding to a blank cell (non-specific binding) was subtracted from the sensogram. Blocking of non-specific protein binding sites and immunofluorescence staining followed by visualization using a laser scanning confocal microscope were performed as previously described (18) .
ITEM4-rGel internalization assay
Cytotoxicity assays
Cytotoxicity of ITEM4-rGel and rGel against various tumor cells was assessed as previously described (18) . Log-phase cells were plated in 96-well flat-bottomed tissue culture plates and allowed to adhere overnight. Purified ITEM4-rGel, rGel and/or ITEM- Apoptosis was assessed using the Annexin V-FITC Kit (Molecular Probes, Inc. Eugene, OR) to distinguish cells that were in the early apoptosis (annexin V+/PI-) or late apoptosis/necrosis (annexin V+/PI+) phase (20) . Apoptosis induction through mitochondrial membrane depolarization was also investigated using the cationic dye JC-1 (MitoProbe, JC-1 Assay Kit) according to manufacturer's instructions.
Lactate dehydrogenase (LDH) release assay
LDH was measured using LDH Cytotoxicity Detection Kit from Clontech Laboratories, Inc. (Mountain View, CA) according to manufacturer's instructions.
Analysis of high-mobility group B1 (HMGB1) cellular release
Whole-cell lysates were resolved on 4-12% Criterion XT Bis-Tris gels (Bio-Rad, Hercules, CA) and transferred to a nitrocellulose membrane as previously described (18) . 
Results
Preparation of ITEM4-rGel immunoconjugate
We utilized the high affinity, murine anti-Fn14 monoclonal antibody ITEM-4 (3) to generate a chemical conjugate with recombinant rGel toxin (designated ITEM4-rGel) using the heterobifunctional cross-linker SPDP as described in Materials and Methods.
The ITEM4-rGel conjugate was purified and the final product was found to contain no contaminating free antibody or rGel as shown in Fig. 1A . Analysis of the preparation confirmed that the final material contained both antibody + 1 rGel (major) and antibody + 2 rGel (minor) species (Fig. 1B) .
The TWEAK receptor Fn14 is overexpressed in multiple tumor cell lines
We next examined Fn14 expression in a panel of normal and tumor cell lines by both Western blot analysis and flow cytometry. (Fig. 2B and 3B ). These data show that the binding affinity and the selectivity of the native ITEM-4 antibody appeared to be unaffected by conjugation to the rGel toxin.
We next examined the ability of ITEM4-rGel to internalize and deliver rGel to the cytoplasm of Fn14-expressing T-24 tumor cells. Immunofluoresence studies showed that exposure of cells to ITEM4-rGel resulted in efficient, rapid internalization of the rGel component to the cytoplasm (Fig. 3C) . It is important to note that in processing treated cells for internalization analysis, the use of brief acid exposure to remove surface-bound immunoconjugate permits preferential detection of internalized conjugate. When these cells were treated with rGel alone, no internalization was detected (Fig. 3C ). In addition, ITEM4-rGel internalization was not observed when the conjugate was added to Fn14-deficient mouse embryonic fibroblasts (data not shown).
ITEM4-rGel is highly cytotoxic to Fn14-expressing tumor cells
We examined the cytotoxic effects of ITEM4-rGel on cell lines expressing various levels of Fn14 to determine the general sensitivity of Fn14-expressing tumor cells and to correlate the cytotoxic effects of the immunoconjugate to Fn14 expression levels. The targeting index (the ratio of IC 50 for rGel vs the IC 50 for ITEM4-rGel) was calculated for each cell line. This ratio represents the ability of the ITEM-4 component of the ITEM4-rGel immunoconjugate to mediate delivery of the rGel toxin component to the target cell cytoplasm and normalizes for the inherent cellular sensitivity to the rGel toxin. As shown in Table 1 , the highest targeting index was found in breast, pancreatic and melanoma tumor lines. The breast tumor cell line eB1 was found to be the most sensitive to ITEM4-rGel (targeting index = 83,500). A number of cell lines which express low levels of Fn14 (eB1, U87-MG and BT474) were nevertheless sensitive to ITEM4-rGel treatment.
Overall, ITEM4-rGel was shown to be 8 -8 x10 4 fold more potent than free rGel. Cell lines which were negative for Fn14 expression were not sensitive to the conjugate. Figure 4A . ITEM4-rGel was able to specifically kill Fn14-expressing cells in a dose-dependent manner, whereas native ITEM-4 antibody alone had no effect at doses of up to 1 μM. By comparison, the cytotoxic effects of ITEM4-rGel on non-target MEF cells were similar to the free rGel with a targeting index of 1. We next examined the minimal contact time required for the ITEM4-rGel conjugate to generate the optimum biological effect. We exposed MDA-MB-231 and T-24 cells to various ITEM4-rGel concentrations for various times ranging from 1 to 72 h.
As summarized in Table 2 , the lowest IC 50 doses were observed after 24 h of exposure and there was no appreciable increase in sensitivity of cells for longer exposure times.
ITEM4-rGel treatment induces apoptosis characterized by HMGB1 release
The mechanisms responsible for the cytotoxicity of ITEM4-rGel were investigated using human T-24 bladder carcinoma cells. These cells were treated with 1 nM rGel, ITEM-4 or ITEM4-rGel for 72 h and then subjected to Annexin Ⅴ and PI staining. Treatment with ITEM4-rGel resulted in a significant increase in Annexin Ⅴ -positive cells suggesting that the conjugate promotes target cell apoptosis (Fig. 5A) . We also demonstrated that exposure of T-24 cells to ITEM4-rGel, but not ITEM-4 or rGel, resulted in mitochondrial membrane depolarization using the mitochondrial dye JC-1 (Fig. 5B) . This finding is also consistent with an apoptotic cell death mechanism. 
It has been reported that most forms of tumor cell death result in release of the RAGE ligand high-mobility group protein 1 (HMGB1) (21) . Therefore, we tested whether HMGB1 would be released from tumor cells following treatment with ITEM4-rGel. We treated T-24 cells with either rGel, ITEM-4 or ITEM4-rGel for 24 h and assessed HMGB1 levels in cell lysates and conditioned media by Western analysis. We observed that treatment of cells with both ITEM-4 and ITEM4-rGel resulted in HMGB1 release (Fig. 5C ). HMGB1 release usually occurs in cells that are undergoing classical necrotic cell death marked by abrupt membrane lysis and the release of soluble proteins (24) . To evaluate the release of another soluble protein, we measured lactate dehydrogenase (LDH) release in treated T-24 cells and found that neither ITEM-4 nor ITEM4-rGel treatment resulted in LDH release (Fig. 5D) . Treatment of cells with the ITEM-4 antibody did not have demonstrable cytotoxic effects nor did it cause measurable apoptotic damage. These data indicate that HMGB1 release from ITEM4-treated cells did not appear to be associated with necrosis but instead may represent selective release of the HMGB1 protein from cells.
ITEM4-rGel localizes in T-24 cell xenograft tumors after intravenous administration
We next investigated whether the ITEM4-rGel conjugate was delivered to xenograft tumors following i.v. injection. The ITEM4-rGel conjugate or PBS were injected into mice bearing T-24 bladder tumors and the tumors were harvested 24 h later. Tumor sections were made and assayed for the presence of ITEM4-rGel by immunofluorescence using an anti-rGel antibody. As shown in Figure 6A rGel-injected mice showed staining with the rGel antibody while there was no staining observed in the saline-treated group. In general, the intratumoral localization of the ITEM4-rGel conjugate (green) appeared to be relatively uniform throughout the tumor sections stained although there were a few areas of intense staining noted.
Inhibition of tumor growth in vivo by ITEM4-rGel
We then determined whether ITEM4-rGel administration could inhibit the growth of T- (Table 1) . Cells over-expressing Fn14 were highly sensitive to the ITEM4-rGel, whereas cells expressing no Fn14 were no more sensitive to the conjugate than they were to free rGel. Surprisingly, some cell lines expressing high (Calu-3) or intermediate (ME-180, HT-29) levels of Fn14 showed relatively low levels of sensitivity to the construct. Alternatively, eB1 breast tumor cells expressing low levels of Fn14 demonstrated extreme sensitivity to the construct. The observed differences in cellular response to the conjugate may be the result of differences in cellular protein synthesis rates, receptor recycling, immunotoxin internalization efficiency (45, 46) or intracellular trafficking and release from endosomal compartments (47) . All of these factors may play a role in determining the ultimate response of cells to the ITEM4-rGel construct.
Our previous studies with rGel-based constructs showed that some constructs induced apoptosis (48) , but some did not and this appeared to be highly dependent on the cell type under investigation (49) . We found that the ITEM4-rGel induced cell death with clear mitochondrial-dependent apoptosis. We additionally showed that when T-24 cells were treated with either ITEM-4 alone or ITEM4-rGel, the protein HMGB1 was released into the media. The effect of unconjugated ITEM-4 on HMGB1 release was unexpected since ITEM-4 showed no effect on the growth of these cells in culture. The effect of permeabilized, and immunostained for the presence of rGel using a rabbit anti-rGel antibody (green). The cells were counterstained with propidium iodide (red) to identify nuclei and visualized using a laser scanning confocal microscope. 
